PMID- 32333155
OWN - NLM
STAT- MEDLINE
DCOM- 20200601
LR  - 20240425
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 99
IP  - 6
DP  - 2020 Jun
TI  - Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking 
      forward to.
PG  - 1161-1176
LID - 10.1007/s00277-020-04028-z [doi]
AB  - Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has 
      significant advantages in spleen reduction and increasing 5-year overall survival 
      (OS), and ruxolitinib-based combinations might provide more benefits than 
      ruxolitinib monotherapy. In this review, we focus on the data of 
      ruxolitinib-based combinations therapies and treatment-related adverse events 
      (AEs) and safety. We analyzed and summarized the data of ruxolitinib-based 
      combinations. Ruxolitinib combined with prednisone + thalidomide + danazol (TPD), 
      panobinostat, pracinostat, azacytidine, or hydroxyurea has well reduced spleen. 
      Ruxolitinib combined with danazol or TPD had well therapies in improvement of 
      hemoglobin (Hgb) and platelets (PLT). Most ruxolitinib-based combinations 
      therapies showed a superior benefit on reduced treatment-related AEs than 
      ruxolitinib monotherapy. Treatment-related AEs and dose modification affect the 
      safety and tolerability of ruxolitinib-based combinations. Genetic testing before 
      treatment is recommended. To provide better clinical guidance, comparisons of 
      these randomized controlled trials with the trials of ruxolitinib alone are 
      necessary. This review suggests that the clinical application of 
      ruxolitinib-based combinations is worth waiting for.
FAU - Li, Yujin
AU  - Li Y
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
AD  - Graduate School, China Academy of Chinese Medical Sciences, Beijing, 100700, 
      China.
FAU - Zhu, Shirong
AU  - Zhu S
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
FAU - Liu, Weiyi
AU  - Liu W
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Ming, Jing
AU  - Ming J
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Wang, Xueying
AU  - Wang X
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
AD  - Graduate School, China Academy of Chinese Medical Sciences, Beijing, 100700, 
      China.
FAU - Hu, Xiaomei
AU  - Hu X
AD  - Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China. huxiaomei_2@163.com.
LA  - eng
GR  - CDA 10-016/HX/HSRD VA/United States
PT  - Journal Article
PT  - Review
DEP - 20200424
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Immunologic Factors)
RN  - 0 (Nitriles)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 82S8X8XX8H (ruxolitinib)
SB  - IM
MH  - Clinical Trials as Topic/methods
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Immunologic Factors/*administration & dosage
MH  - Nitriles
MH  - Primary Myelofibrosis/diagnosis/*drug therapy
MH  - Pyrazoles/*administration & dosage
MH  - Pyrimidines
MH  - Treatment Outcome
PMC - PMC7237512
OTO - NOTNLM
OT  - Hematology
OT  - Myelofibrosis
OT  - Ruxolitinib
OT  - Ruxolitinib-based combinations
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/04/26 06:00
MHDA- 2020/06/02 06:00
PMCR- 2020/04/24
CRDT- 2020/04/26 06:00
PHST- 2020/03/06 00:00 [received]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/06/02 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/24 00:00 [pmc-release]
AID - 10.1007/s00277-020-04028-z [pii]
AID - 4028 [pii]
AID - 10.1007/s00277-020-04028-z [doi]
PST - ppublish
SO  - Ann Hematol. 2020 Jun;99(6):1161-1176. doi: 10.1007/s00277-020-04028-z. Epub 2020 
      Apr 24.